

Primary Series and Boosters — No Impact on Maternal COVID-19 Test Positivity

Large Study Published in BMJ Ignored Safety, Found No Benefit with Dangerous Injections

By [Dr. Peter McCullough](#)

Theme: [Science and Medicine](#)

Global Research, March 21, 2023

[Courageous Discourse](#)

All Global Research articles can be read in 51 languages by activating the Translate Website button below the author's name.

To receive Global Research's Daily Newsletter (selected articles), [click here](#).

Follow us on [Instagram](#) and [Twitter](#) and subscribe to our [Telegram Channel](#). Feel free to repost and share widely Global Research articles.

My attention was recently drawn by a commentary from Emily Harris in JAMA implying that COVID-19 vaccination during pregnancy had benefits from a study previously published in the British Medical Journal. There has never been any randomized, prospective, double-blind placebo controlled trial of COVID-19 vaccines in any group demonstrating clinical benefit defined as reductions in hospitalization and death. Among pregnant women, COVID-19 vaccination is category X, meaning it should not be given. So naturally I was suspicious on how a report indicating benefit made into the British Medical Journal. The literature is accumulating numerous invalid analyses making false claims of benefit without adequate design or consideration of drug safety.

Jorgensen et al published from the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network Investigators a study from automated sources of data on pregnant women and infants tested using nasal PCR-testing. As a former editor I found this paper misleading because: 1) diagnostic codes for safety events (heart damage, blood clots, stroke, maternal death) were not disclosed and analyzed, 2) no adjudication for COVID-19 illness, so healthy test positive "cases" were reported, 3) focus was on infants was irrelevant since they not develop clinically significant COVID-19.

The interesting finding in the Jorgensen paper, not mentioned by the authors is in the Table. As you can see, primary series and boosters had no statistically significant impact in test positivity among the mothers. This means the intervention was completely useless and had no laboratory or clinical benefit reported.



Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study

Sarah C J Jorgensen,¹ Alejandro Hernandez,² Deshayne B Fell,^{2,4} Peter C Austin,^{2,5} Rohan D'Souza,^{6,7} Astrid Guttman,^{2,5,8,9} Kevin A Brown,^{2,10,11} Sarah A Buchan,^{2,10,12} Jonathan B Gubbay,^{11,13} Sharifa Nasreen,^{2,10} Kevin L Schwartz,^{2,10,11} Mina Tadrous,^{2,14,15} Kumanan Wilson,^{16,17,18} Jeffrey C Kwong,^{2,10,12,19,20} on behalf of the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators

Cite this as: *BMJ* 2023;380:e074035
<http://dx.doi.org/10.1136/bmj-2022-074035>

Accepted: 12 January 2022

Table 1 | Characteristics of infants younger than six months of age tested for SARS-CoV-2 infection, May 2021 to September 2022, and their mothers, Ontario, Canada. Data are number (percentage), unless otherwise specified

Characteristic	Infants (<6 months) tested for SARS-CoV-2			Maternal covid-19 vaccination status					
	Case (n=1600)	Control (n=7209)	SD*	Unvaccinated (n=3293)	Primary and primary + boostert (n=5516)	SD*	Primary† (n=4825)	Primary plus boostert (n=691)	SD*
Infant sex, female	742 (46.4)	3161 (43.8)	0.05	1506 (45.7)	2397 (43.5)	0.05	2111 (43.8)	286 (41.4)	0.05
Infant age when tested:									
0-8 weeks	525 (32.8)	4111 (57.0)	0.50	1849 (56.1)	2787 (50.5)	0.11	2352 (48.7)	435 (63.0)	0.29
9-16 weeks	585 (36.6)	1816 (25.2)	0.25	802 (24.4)	1599 (29.0)	0.10	1435 (29.7)	164 (23.7)	0.14
>16 weeks	490 (30.6)	1282 (17.8)	0.30	642 (19.5)	1130 (20.5)	0.02	1038 (21.5)	92 (13.3)	0.22
Gestational age at birth (weeks), median (interquartile range)	39 (38-40)	39 (37-39)	0.23	39 (37-40)	39 (38-39)	0.01	39 (38-39)	39 (38-39)	0.02
Preterm birth‡	109 (6.8)	985 (13.7)	0.23	426 (12.9)	668 (12.1)	0.02	576 (11.9)	92 (13.3)	0.04
Low birthweight§	86 (5.4)	813 (11.3)	0.21	365 (11.1)	534 (9.7)	0.05	472 (9.8)	62 (9.0)	0.03
Mother's age at birth:									
<25 years	192 (12.0)	703 (9.8)	0.07	571 (17.3)	324 (5.9)	0.36	297 (6.2)	27 (3.9)	0.10
25-29 years	399 (24.9)	1745 (24.2)	0.02	956 (29.0)	1188 (21.5)	0.17	1076 (22.3)	112 (16.2)	0.15
30-34 years	591 (36.9)	2768 (38.4)	0.03	1038 (31.5)	2321 (42.1)	0.22	2009 (41.6)	312 (45.2)	0.07
35-39 years	346 (21.6)	1641 (22.8)	0.03	577 (17.5)	1410 (25.6)	0.20	1205 (25.0)	205 (29.7)	0.11
≥40 years	72 (4.5)	352 (4.9)	0.02	151 (4.6)	273 (4.9)	0.02	238 (4.9)	35 (5.1)	0.01
Nulliparous	853 (53.3)	4393 (60.9)	0.15	1935 (58.8)	3311 (60.0)	0.03	2939 (60.9)	372 (53.8)	0.14
Pre-pregnancy maternal comorbidities:									
Diabetes mellitus	93 (5.8)	447 (6.2)	0.02	198 (6.0)	342 (6.2)	0.01	317 (6.6)	25 (3.6)	0.13
Hypertension	42 (2.6)	179 (2.5)	0.01	81 (2.5)	140 (2.5)	0.01	118 (2.4)	22 (3.2)	0.04
Heart disease	≤5 (≤0.3)¶	≤5 (≤0.1)¶	0-0.06¶	≤5 (≤0.2)¶	≤5 (≤0.1)¶	0-0.02¶	≤5 (≤0.1)¶	0 (0.0)	0-0.01¶
Asthma	307 (19.2)	1498 (20.8)	0.04	686 (20.8)	1119 (20.3)	0.01	981 (20.3)	138 (20.0)	0.01
Autoimmune disease	46 (2.9)	203 (2.8)	0	72 (2.2)	177 (3.2)	0.06	148 (3.1)	29 (4.2)	0.06
Immunosuppression**	31 (1.9)	189 (2.6)	0.05	72 (2.2)	148 (2.7)	0.03	127 (2.6)	21 (3.0)	0.02
Prenatal care index††:									
Intensive/intermediate	845 (52.8)	3598 (49.9)	0.06	1606 (48.8)	2837 (51.4)	0.05	2480 (51.4)	357 (51.7)	0.01
Adequate	253 (15.8)	1109 (15.4)	0.01	483 (14.7)	879 (15.9)	0.04	767 (15.9)	112 (16.2)	0.01
Inadequate	370 (23.1)	1796 (24.9)	0.04	872 (26.5)	1294 (23.5)	0.07	1120 (23.2)	174 (25.2)	0.05
No care	132 (8.3)	706 (9.8)	0.05	332 (10.1)	506 (9.2)	0.03	458 (9.5)	48 (6.9)	0.09
Maternal influenza vaccine‡‡	381 (23.8)	2095 (29.1)	0.12	381 (11.6)	2095 (38.0)	0.64	1804 (37.4)	291 (42.1)	0.10
Maternal SARS-CoV-2 infection:									
Pre-pregnancy	28 (1.8)	179 (2.5)	0.05	80 (2.4)	127 (2.3)	0.01	100 (2.1)	27 (3.9)	0.11
During pregnancy	69 (4.3)	834 (11.6)	0.27	425 (12.9)	478 (8.7)	0.14	381 (7.9)	97 (14.0)	0.20
Post partum	324 (20.3)	365 (5.1)	0.47	309 (9.4)	380 (6.9)	0.09	348 (7.2)	32 (4.6)	0.11

Jorgensen SCJ, Hernandez A, Fell DB, Austin PC, D'Souza R, Guttman A, Brown KA, Buchan SA, Gubbay JB, Nasreen S, Schwartz KL, Tadrous M, Wilson K, Kwong JC; Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators. Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study. *BMJ*. 2023 Feb 8;380:e074035. doi: 10.1136/bmj-2022-074035. PMID: 36754426; PMCID: PMC9903336.

The medical literature is burgeoning with fraudulent papers extolling false claims of COVID-19 vaccination from nonrandomized, non-adjudicated data while at the same time ignoring horrific safety outcomes well known to occur as a result of vaccination. Jorgensen and the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network Investigators can be added to this long list of culpable authors. The conclusions of this paper serve as a stark warning to view the primary data and realize the authors are biased and not fairly evaluating these emerging potentially dangerous genetic biotechnologies.

If you find "Courageous Discourse" enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in

these discussions with family, friends, and your extended circles.

*

Note to readers: Please click the share buttons above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.


Sources

[Harris E. COVID-19 Vaccination During Pregnancy Protected Infants. JAMA. 2023;329\(10\):789. doi:10.1001/jama.2023.2098](https://doi.org/10.1001/jama.2023.2098)

[COVID-19 Vaccines Remain Pregnancy Category X Products Should Never Have Been Administered in Pregnant Women and Those of Childbearing Age](#)

[Jorgensen SCJ, Hernandez A, Fell DB, Austin PC, D'Souza R, Guttman A, Brown KA, Buchan SA, Gubbay JB, Nasreen S, Schwartz KL, Tadrous M, Wilson K, Kwong JC; Canadian Immunization Research Network \(CIRN\) Provincial Collaborative Network \(PCN\) Investigators. Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study. BMJ. 2023 Feb 8;380:e074035. doi: 10.1136/bmj-2022-074035. PMID: 36754426; PMCID: PMC9903336.](#)

Featured image is from Children's Health Defense



The Worldwide Corona Crisis, Global Coup d'Etat Against Humanity

by Michel Chossudovsky

Michel Chossudovsky reviews in detail how this insidious project “destroys people’s lives”. He provides a comprehensive analysis of everything you need to know about the “pandemic” — from the medical dimensions to the economic and social repercussions, political underpinnings, and mental and psychological impacts.

“My objective as an author is to inform people worldwide and refute the official narrative which has been used as a justification to destabilize the economic and social fabric of entire countries, followed by the imposition of the “deadly” COVID-19 “vaccine”. This crisis affects humanity in its entirety: almost 8 billion people. We stand in solidarity with our fellow human beings and our children worldwide. Truth is a powerful instrument.”

[Conservative Risk Benefit Analyses Decide Against COVID-19 Vaccination](#)

ISBN: 978-0-9879389-3-0, Year: 2022, PDF Ebook, Pages: 164, 15 Chapters

Price: ~~\$11.50~~ Get yours for FREE! [Click here to download.](#)

We encourage you to support the eBook project by making a donation through Global Research's [DonorBox "Worldwide Corona Crisis" Campaign Page.](#)

The original source of this article is [Courageous Discourse](#)
Copyright © [Dr. Peter McCullough](#), [Courageous Discourse](#), 2023

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Dr. Peter
McCullough](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca